Dr Ignacio Faus,
Chief Executive Officer (CEO)

Dr Ignacio Faus joined the Executive Board of MOLOGEN AG in August 2018 as Chief Executive Officer. 

He has more than 25 years of experience in the life sciences industry, having worked for several globally operating pharmaceutical companies (BMS, Ferrer International, Grupo Uriach), where he acquired valuable experience in fundraising, organizational planning, strategic project evaluation, operational efficiency, business development & licensing, etc..

In 2006 he was one of the founders of PALAU PHARMA, a spin-out of Grupo Uriach´s inflammation and autoimmune diseases R&D Unit. From 2006 to 2013 he led the company as CEO through two venture rounds (more than €50 million raised), two joint ventures that generated commercialized products and the sale / license of several Research & Development (R&D) projects to top-tier pharmaceuticals companies. PALAU PHARMA was successfully divested in 2013.

For his role in PALAU PHARMA he was honored with the “Corporate Transaction of the Year Award”, earning personal congratulations from then Prince (now King) Felipe VI of Spain.

In recent years he has held several advisory roles, consulting engagements and Board of Directors memberships. 

He is currently member of the Board of Directors of several Private Equity funds managed by DRI Capital (Toronto, Canada). He is also President of Abologix Sàrl, a biotech start-up recently created in Geneva, Switzerland.

After he completed his PhD in Biochemistry in 1988 (Indiana University Bloomington, US), he achieved a Master of Business Administration (MBA) in Finance, Innovation and Marketing from Kellogg School of Management, Northwestern University, US in 1993 and also the CEO Executive Education Program (PDG) at IESE Business School in Barcelona (2004).

Dr Faus was born in 1962 and is a Spanish citizen. He is married and has two children.

Areas of responsibility at MOLOGEN:

  • Business Development
  • Investor Relations & Corporate Communications
  • Partnering
  • Production
  • Strategy

External mandates:

  • DRI Capital, Member of the Board of Directors of several Private Equity funds managed by DRI Capital   
  • ABOLOGIX Sàrl, President

Walter Miller,
Chief Financial Officer (CFO)

Walter Miller became the new Chief Financial Officer of MOLOGEN AG in April 2016.

He has more than 15 years of experience in the biotech and pharmaceutical industry, in both startups and listed companies. In 2013, he became the authorized signatory and commercial director (CFO) of Nuvisan GmbH, Germany, an international contract research organization (CRO) and laboratory service provider, where he assumed responsibility for the commercial and administrative areas of the company. Prior to this, between 2002 and 2013, he held various management positions in the Santhera Pharmaceuticals Group, initially in Germany and later in Switzerland, most recently as Vice President Finance & Commercial Operations and as a Member of the Executive Board. In particular, his remit included the development of the organization, the accounting system and project controlling as well as handling strategic financial matters and in- and out-licensing activities. Furthermore, he was significantly involved in the cross-border merger, the initial public offering (IPO) on the SIX Swiss Exchange and various financing deals.

Before entering the biotech and pharmaceutical industry, Walter Miller’s last position was as Head of Accounting and Controlling at Parsytec AG, Germany. In this role, his responsibility covered the Group’s international consolidated financial statements in accordance with US-GAPP, project controlling and the finances of foreign subsidiaries. In addition, he was on the IPO team in 1999.

Walter Miller obtained his qualification for Business Administration (FH) in Aachen, Germany,
in 1997. He was also awarded a Baccalaureate in the Science of Marriage and Family in 1994 (comparable with a Bachelor of Arts) and the Controller’s Diploma at the Controller Akademie Gauting, near Munich, in 2004.

He was born in 1967 and has the German citizenship. Walter Miller is married and has a son.

Areas of responsibility at MOLOGEN:

  • Compliance and Corporate Governance
  • Finance and Administration 
  • Human Resources
  • IT
  • Legal
  • Risk Management

External mandates:

  • Walter Miller currently does not hold any other board memberships.

Dr. Matthias Baumann,
Chief Medical Officer (CMO)

Dr Baumann joined Mologen in May 2017 as Chief Medical Officer and Member of the Executive Board.

He has more than 26 years of experience in the healthcare industry. He has a strong background in medical sciences and has worked on a broad range of indications and development approaches for chemical and biotechnological compounds.

Before joining MOLOGEN, he worked in various management positions with increasing responsibility in the international pharmaceutical, CRO and biotech industries.

From 2011 to 2017 he served as Chief Medical Officer and member of the Executive Board of NOXXON Pharma AG, a Berlin-based biotech 

company focused on novel cancer therapies. Here he was responsible for the planning and conduct of clinical development programs that brought three candidate molecules to clinical proof of concept.

From 2002 to 2010 he served as Chief Scientific Officer and Managing Director of FOCUS Clinical Drug Development, Neuss/Düsseldorf. In this role he was responsible for the design and execution of integrated programs progressing development compounds from the preclinical candidate stage to clinical proof of concept.

Prior to working for FOCUS, he served in various research and development roles at Roche and Boehringer Mannheim.

After receiving his MD degree from the University of Erlangen, Germany in 1984, Dr Baumann pursued 5 years of postgraduate training in the fields of oncology and immunology in Germany and the U.S.

He was born in 1958 and has the German citizenship. Dr Baumann is married.

Areas of responsibility at MOLOGEN:

  • Clinical Strategy
  • Preclinical & Clinical Development 
  • Regulatory Affairs
  • Research

External mandates:

  • Dr Baumann currently does not hold any other board memberships.

Fabeckstrasse 30
D - 14195 Berlin

T.  +49 (0)30 - 84 17 88 - 0
F.  +49 (0)30 - 84 17 88 - 50